about
Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and MetaanalysisVorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.Ultrasound guided pericardial drainage and intrapericardial instillation of mitomycin C for malignant pericardial effusion.Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression.Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells.Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.Acquisition of Mycobacterium abscessus among ventilator-dependent patients in Taiwan chronic respiratory care facilities.Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells.Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells.HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination.Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: clinical features and susceptibilities of the isolates.Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study.Cementing an unwanted relationship.Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study.Superior vena cava syndrome. Rapid histologic diagnosis by ultrasound-guided transthoracic needle aspiration biopsyClinical characteristics and outcomes of patients with pleural infections due to Stenotrophomonas maltophilia at a medical center in Taiwan, 2004-2012Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer CellsClinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort studyOutcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort studyInhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cellsCapsaicin enhances erlotinib-induced cytotoxicity via AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cellsFactors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE studyAfatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
P50
Q33589264-49AF6238-1552-41B3-9832-7725D41551FEQ36184617-24005918-3028-4FB5-847B-C64FE977CC1FQ36568512-B3501AD9-CC79-472C-9BC0-50FA015191A6Q38743830-C0150F1D-3CE7-4636-A24D-4FE8F1DA58B4Q38790582-3B332144-AA95-45C7-BCD3-60913E498B2DQ38849092-686CADFA-5AC3-4BC7-BFC3-B271461F64DCQ38867098-F9A437B3-E5B7-4D98-A566-888F25858E05Q38883159-D25F77D6-D162-4AAA-A586-D366FB676FAAQ38930621-F838F0FF-B736-4F12-9E41-5C86FB579ADCQ39032303-3E4DB167-EB69-400F-974D-4A06D121BC2FQ39076940-1DD9141E-C95D-4536-954D-E1A671C61AB0Q39202165-A70866B1-31DD-49DA-9D78-60F32174F2F4Q39258864-FDAA7F7E-695D-4D2D-B077-484CD9202DE0Q39618531-E1B7B3D0-705E-4AA1-BE57-7CFACCC973C1Q39813901-C65AF6E8-BC64-4981-8376-38A3276EFDC9Q39918789-5C20C800-0044-48B7-907E-C7AF4AE30BBEQ39996855-6098E945-E0B4-4618-BD4F-5F10479E65CDQ40975815-664829A7-5F41-4C13-A1E5-A64D42EB14BBQ41498410-30716C39-5B38-47E5-AB27-0D1923189764Q42357130-BD6476D0-D247-4F4A-85E6-C11C9492CC00Q44234835-FC5ED621-30FA-4E3E-8468-21B484FEC95EQ46547397-C8A5B553-B10A-4854-A907-61B808FB270BQ47102256-D4C743CE-9DD6-437E-9A75-C74EED3D2C03Q47660376-2BDE0FAB-A276-415B-B0E9-A3613996F13DQ48222109-1D459C05-158E-460A-ABF3-B3155291D4B4Q55035103-F2356647-A83C-4A85-9C3D-9620AF42BC17Q72269174-F7380670-5AB8-4010-96CC-FA1F765CD13DQ87156332-CFB1ED88-5DE3-45D1-998B-186AB6296488Q90823959-63253153-CD37-4BEB-98B4-B0E645426D10Q91524964-38A0C213-D019-49FC-85ED-0DB0233756DAQ91529164-43670C33-AA70-4D8A-A08D-35AEECC44F3CQ91849931-506441DB-F235-486C-95EB-6328C70199F4Q92504315-63898739-2185-4767-9BA9-08E08DC2BBE5Q92651193-55E57CE9-C088-422A-8461-19C0320808BFQ92757886-DEEA6730-D37E-4516-B8E5-7C7309711122
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jen-Chung Ko
@ast
Jen-Chung Ko
@en
Jen-Chung Ko
@es
Jen-Chung Ko
@nl
type
label
Jen-Chung Ko
@ast
Jen-Chung Ko
@en
Jen-Chung Ko
@es
Jen-Chung Ko
@nl
prefLabel
Jen-Chung Ko
@ast
Jen-Chung Ko
@en
Jen-Chung Ko
@es
Jen-Chung Ko
@nl
P106
P1153
7402678857
P31
P496
0000-0001-8543-1990